RDY
DR Reddys Laboratories Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
DR Reddys Laboratories Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
No other changes.
No other changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
20-F parsed · May 29 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · May 29 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
−0.15%
vs ±7.4% implied · ×0.02
shaded = implied · ▲▼ = realized
DR Reddys Laboratories Ltd
14.18
pre 13.81 −2.52%
Expected move
No implied move.
Linked news
Closest co-movers of DR Reddys Laboratories Ltd; it has no SEC industry code.
Closest co-movers of DR Reddys Laboratories Ltd; it has no SEC industry code.
Closest co-movers · 500d
NVSNovartis×0.25r 0.30CBLLCeribell×0.74r 0.29GEHCGE HealthCare Technologies×0.39r 0.28MMM| Manager | Value | % base | |
|---|---|---|---|
| Robeco Institutional Asset Management B.V. | $261.1M | 14.36% | +4.91% |
| Morgan Stanley | $158.5M | 8.71% | +16.70% |
| BlackRockindex-like | $153.4M | 8.43% | −8.64% |
| Royal Bank of Canada | $133.5M | 7.34% | −7.72% |
| Aikya | $123.1M | 6.77% | +6.18% |
| Manager | Value | % base | |
|---|---|---|---|
| Robeco Institutional Asset Management B.V. | $261.1M | 14.36% | +4.91% |
| Morgan Stanley | $158.5M | 8.71% | +16.70% |
| BlackRockindex-like | $153.4M | 8.43% | −8.64% |
| Royal Bank of Canada | $133.5M | 7.34% | −7.72% |
| Aikya | $123.1M | 6.77% | +6.18% |